Biotech Lock-Up Expiration Hell Portfolio Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (896)	2/27/2004 6:05:00 PM
From: tuck	Read Replies (2) of 1005

Here's the article about GenVec's (GNVC) TNFerade trial and an accompanying editorial, both from JCO, and both free full text. The main beef with the trial seems to be that response was not conclusively tied to vector dose, and no measurements of expression and such were done to evaluate the important "bystander" effect. Part expense and part ethics, I suppose, as the gathering of that info would have required invasive techniques (though maybe PET would have done the job?). . . . jco.org Editorial: jco.org Still curious as to exactly what your concerns are. Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next